Tyra Biosciences (TYRA) Shares Plunge 22% as Bladder Cancer Drug Trial Falls Short
TLDR Shares of Tyra Biosciences plummeted 22% to $20.96 following underwhelming Phase 2 clinical trial results for its bladder cancer medication dabogratinib The experimental therapy achieved





